OTCPK:APNHY (South africa) Also trade in: Germany South Africa

Aspen Pharmacare Holdings Ltd

$ 7.17 0.02 (0.28%)
Volume: 8,976 Avg Vol (1m): 22,646
Market Cap $: 3.35 Bil Enterprise Value $: 7.08 Bil
P/E (TTM): 8.79 P/B: 0.91
Earnings Power Value 2.34
Net Current Asset Value -5.56
Tangible Book -3.44
Projected FCF 8.55
Median P/S Value 23.36
Graham Number 0
Peter Lynch Value 9.52
DCF (FCF Based) -0.26
DCF (Earnings Based) 20.23
YTD (-%)

Financial Strength : 5/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 0.16
Cash-To-Debt ranked lower than
85.56% of 859 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 91151, Med: 2.03, Min: -0.01
APNHY: 0.16
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.16, Med: 0.32, Max: 128.44
Current: 0.16
0.16
128.44
Equity-to-Asset 0.39
Equity-to-Asset ranked lower than
82.36% of 788 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 1.78, Med: 0.64, Min: -27.83
APNHY: 0.39
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: 0.31, Med: 0.4, Max: 0.55
Current: 0.39
0.31
0.55
Debt-to-Equity 1.21
Debt-to-Equity ranked lower than
86.91% of 596 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 31.22, Med: 0.32, Min: 0.01
APNHY: 1.21
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: 0.01, Med: 0.88, Max: 1.55
Current: 1.21
0.01
1.55
Debt-to-EBITDA 6.87
Debt-to-EBITDA ranked lower than
81.01% of 495 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 343059.67, Med: 1.92, Min: 0.01
APNHY: 6.87
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: 2.14, Med: 3.64, Max: 6.87
Current: 6.87
2.14
6.87
Interest Coverage 4.25
Interest Coverage ranked lower than
83.49% of 648 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 2689668, Med: 86.08, Min: 0.01
APNHY: 4.25
Ranked among companies with meaningful Interest Coverage only.
Interest Coverage range over the past 10 years
Min: 3.11, Med: 4.86, Max: 5.98
Current: 4.25
3.11
5.98
Piotroski F-Score 6
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 1.41
DISTRESS
GREY
SAFE
Beneish M-Score -2.44
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 8.56%
WACC 8.98%

Profitability & Growth : 8/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % 24.07
Operating Margin ranked higher than
82.40% of 801 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 8950, Med: 7.97, Min: -232970.37
APNHY: 24.07
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: 23.27, Med: 25.6, Max: 28.65
Current: 24.07
23.27
28.65
Net Margin % 12.40
Net Margin ranked higher than
76.18% of 802 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 304900, Med: 5.32, Min: -216285.19
APNHY: 12.4
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: 12.08, Med: 16.51, Max: 20.82
Current: 12.4
12.08
20.82
ROE % 10.85
ROE ranked higher than
75.24% of 832 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 316.96, Med: 5.94, Min: -3119.47
APNHY: 10.85
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: 10.85, Med: 17.97, Max: 36.01
Current: 10.85
10.85
36.01
ROA % 4.08
ROA ranked higher than
60.96% of 871 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 943.36, Med: 2.88, Min: -1851.14
APNHY: 4.08
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: 4.08, Med: 8.48, Max: 12.24
Current: 4.08
4.08
12.24
ROC (Joel Greenblatt) % 35.21
ROC (Joel Greenblatt) ranked higher than
87.60% of 855 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 34233.33, Med: 11.23, Min: -2671900
APNHY: 35.21
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: 32.99, Med: 49.85, Max: 79.26
Current: 35.21
32.99
79.26
3-Year Total Revenue Growth Rate 5.70
3-Year Revenue Growth Rate ranked higher than
69.81% of 689 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 291.9, Med: 5.8, Min: -100
APNHY: 5.7
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: 5.7, Med: 22.6, Max: 33.4
Current: 5.7
5.7
33.4
3-Year Total EBITDA Growth Rate 3.30
3-Year EBITDA Growth Rate ranked lower than
56.82% of 704 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 299.6, Med: 7.3, Min: -343.2
APNHY: 3.3
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: 2, Med: 24.1, Max: 46.5
Current: 3.3
2
46.5
3-Year EPS w/o NRI Growth Rate 4.90
3-Year EPS w/o NRI Growth Rate ranked lower than
62.29% of 663 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 385.8, Med: 8.9, Min: -403.2
APNHY: 4.9
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0.8, Med: 26, Max: 365.5
Current: 4.9
0.8
365.5

» APNHY's 30-Y Financials

Financials (Next Earnings Date: )

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with OTCPK:APNHY

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS : 0    SIC : 0
Compare SZSE:000513 TSE:4527 SZSE:000623 XCNQ:GTII XCNQ:CURA TSE:4530 LIM:BAYERI1 NSE:ALKEM XTER:EVT HKSE:02005 SHSE:600277 SHSE:600511 BUD:RICHTER NYSE:AMRX BOM:532296 SHSE:600521 HKSE:00460 SHSE:603707 SZSE:002038 SZSE:000999
Traded in other countries LDZA.Germany APN.South Africa
Address Woodlands Drive, Woodmead, PO Box 1587, Gallo Manor, Building Number 8, Healthcare Park, Johannesburg, ZAF, 2052
Aspen Pharmacare Holdings Ltd is a specialty and generic drug manufacturing company. The company maintains a focus on four therapeutic categories: thrombosis, anaesthetics, high potency and cytotoxics, and infant nutritionals. Aspen generates the vast majority of its revenue through its commercial-pharma segment, followed by manufacturing and commercial-nutritionals segments. The company considers potential merger and acquisition investment a component of its operational growth strategy to expand its research, development, manufacturing, and marketing capabilities.

Ratios

Current vs industry vs history
PE Ratio (TTM) 9.05
PE Ratio ranked higher than
64.63% of 557 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 1910, Med: 23.77, Min: 0.06
APNHY: 9.05
Ranked among companies with meaningful PE Ratio only.
PE Ratio range over the past 10 years
Min: 6.92, Med: 23.07, Max: 40.2
Current: 9.05
6.92
40.2
PE Ratio without NRI 8.79
PE without NRI ranked higher than
66.01% of 556 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 2125, Med: 24.2, Min: 0.06
APNHY: 8.79
Ranked among companies with meaningful PE without NRI only.
PE without NRI range over the past 10 years
Min: 6.92, Med: 23.98, Max: 40.2
Current: 8.79
6.92
40.2
Price-to-Owner-Earnings 12.59
Price-to-Owner-Earnings ranked lower than
58.95% of 324 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 3160, Med: 31.95, Min: 0.17
APNHY: 12.59
Ranked among companies with meaningful Price-to-Owner-Earnings only.
Price-to-Owner-Earnings range over the past 10 years
Min: 10.92, Med: 43.44, Max: 132.77
Current: 12.59
10.92
132.77
PB Ratio 0.91
PB Ratio ranked lower than
50.43% of 819 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 227.39, Med: 2.64, Min: 0.05
APNHY: 0.91
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 0.83, Med: 3.89, Max: 7.5
Current: 0.91
0.83
7.5
PS Ratio 1.13
PS Ratio ranked higher than
52.13% of 775 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 9105.26, Med: 3.1, Min: 0.03
APNHY: 1.13
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 0.98, Med: 3.67, Max: 6.78
Current: 1.13
0.98
6.78
Price-to-Operating-Cash-Flow 6.83
Price-to-Operating-Cash-Flow ranked higher than
59.69% of 392 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 14229.87, Med: 22, Min: 0.23
APNHY: 6.83
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 5.93, Med: 22.62, Max: 54.21
Current: 6.83
5.93
54.21
EV-to-EBIT 10.99
EV-to-EBIT ranked higher than
52.45% of 572 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 1015380.11, Med: 17.85, Min: 0.13
APNHY: 10.99
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: 9.1, Med: 18.4, Max: 29.5
Current: 10.99
9.1
29.5
EV-to-EBITDA 10.99
EV-to-EBITDA ranked lower than
55.95% of 597 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 341528.02, Med: 15.24, Min: 0.12
APNHY: 10.99
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: 8.3, Med: 17, Max: 26.7
Current: 10.99
8.3
26.7
EV-to-Revenue 2.38
EV-to-Revenue ranked lower than
53.71% of 795 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 23858.8, Med: 3.24, Min: 0.03
APNHY: 2.38
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 2.1, Med: 4.4, Max: 7.8
Current: 2.38
2.1
7.8
PEG Ratio 0.75
PEG Ratio ranked higher than
67.19% of 317 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 1472, Med: 1.93, Min: 0.07
APNHY: 0.75
Ranked among companies with meaningful PEG Ratio only.
PEG Ratio range over the past 10 years
Min: 0.37, Med: 1.06, Max: 2.09
Current: 0.75
0.37
2.09
Shiller PE Ratio 11.71
Shiller PE Ratio ranked lower than
51.19% of 252 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 1460.4, Med: 32.75, Min: 0.08
APNHY: 11.71
Ranked among companies with meaningful Shiller PE Ratio only.
Shiller PE Ratio range over the past 10 years
Min: 10.15, Med: 50.95, Max: 91.03
Current: 11.71
10.15
91.03
Current Ratio 2.05
Current Ratio ranked lower than
89.94% of 855 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 413.44, Med: 2.39, Min: 0.02
APNHY: 2.05
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.7, Med: 1.4, Max: 2.05
Current: 2.05
0.7
2.05
Quick Ratio 1.34
Quick Ratio ranked lower than
91.93% of 855 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 413.44, Med: 1.87, Min: 0.02
APNHY: 1.34
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.49, Med: 0.96, Max: 1.34
Current: 1.34
0.49
1.34
Days Inventory 252.95
Days Inventory ranked lower than
84.77% of 755 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 950.68, Med: 119.8, Min: 0.2
APNHY: 252.95
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 115.22, Med: 150.76, Max: 259.83
Current: 252.95
115.22
259.83
Days Sales Outstanding 113.90
Days Sales Outstanding ranked lower than
73.77% of 770 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 864.61, Med: 81.76, Min: 0.1
APNHY: 113.9
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 79.88, Med: 92.21, Max: 113.9
Current: 113.9
79.88
113.9
Days Payable 162.35
Days Payable ranked higher than
79.55% of 758 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 952.38, Med: 76.32, Min: 0.04
APNHY: 162.35
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 72.18, Med: 118, Max: 162.35
Current: 162.35
72.18
162.35

Dividend & Buy Back

Current vs industry vs history
Dividend Yield % 2.95
Trailing Dividend Yield ranked lower than
62.77% of 752 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 25.84, Med: 1.54, Min: 0.04
APNHY: 2.95
Ranked among companies with meaningful Trailing Dividend Yield only.
Trailing Dividend Yield range over the past 10 years
Min: 0.36, Med: 0.72, Max: 3.15
Current: 2.95
0.36
3.15
Dividend Payout Ratio 0.25
Dividend Payout Ratio ranked higher than
65.83% of 477 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 68, Med: 0.3, Min: 0.02
APNHY: 0.25
Ranked among companies with meaningful Dividend Payout Ratio only.
Dividend Payout Ratio range over the past 10 years
Min: 0.14, Med: 0.19, Max: 0.25
Current: 0.25
0.14
0.25
3-Year Dividend Growth Rate (Per Share) 15.10
3-Year Dividend Growth Rate ranked higher than
72.91% of 299 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 114, Med: 7.4, Min: -100
APNHY: 15.1
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
3-Year Dividend Growth Rate range over the past 10 years
Min: 0, Med: 15.1, Max: 63.4
Current: 15.1
0
63.4
Forward Dividend Yield % 2.97
Forward Dividend Yield ranked lower than
66.48% of 719 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 25.84, Med: 1.66, Min: 0.04
APNHY: 2.97
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield-on-Cost (5-Year) % 5.63
Yield-on-Cost (5y) ranked higher than
59.60% of 745 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 42.46, Med: 2.12, Min: 0.03
APNHY: 5.63
Ranked among companies with meaningful Yield-on-Cost (5y) only.
Yield-on-Cost (5y) range over the past 10 years
Min: 0.69, Med: 1.37, Max: 6.01
Current: 5.63
0.69
6.01

Valuation & Return

Current vs industry vs history
Price-to-Projected-FCF 0.84
Price-to-Intrinsic-Value-Projected-FCF ranked lower than
100.00% of 374 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 209, Med: 2.11, Min: 0.05
APNHY: 0.84
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 0.84, Med: 3.61, Max: 5.84
Current: 0.84
0.84
5.84
Price-to-DCF (Earnings Based) 0.35
Price-to-Intrinsic-Value-DCF (Earnings Based) ranked higher than
86.36% of 110 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 27.76, Med: 1.36, Min: 0.14
APNHY: 0.35
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
Price-to-Intrinsic-Value-DCF (Earnings Based) range over the past 10 years
Min: 0.79, Med: 1, Max: 1.35
Current: 0.35
0.79
1.35
Price-to-Median-PS-Value 0.31
Price-to-Median-PS-Value ranked lower than
100.00% of 743 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 238.36, Med: 0.94, Min: 0.01
APNHY: 0.31
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.31, Med: 0.9, Max: 1.46
Current: 0.31
0.31
1.46
Price-to-Peter-Lynch-Fair-Value 0.75
Price-to-Peter-Lynch-Fair-Value ranked lower than
100.00% of 212 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 26.42, Med: 1.41, Min: 0.08
APNHY: 0.75
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
Price-to-Peter-Lynch-Fair-Value range over the past 10 years
Min: 0.54, Med: 1.25, Max: 1.85
Current: 0.75
0.54
1.85
Earnings Yield (Joel Greenblatt) % 9.10
Earnings Yield (Greenblatt) ranked higher than
68.63% of 867 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 769.23, Med: 3.31, Min: -333.33
APNHY: 9.1
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: 3.4, Med: 5.4, Max: 11
Current: 9.1
3.4
11
Forward Rate of Return (Yacktman) % 13.01
Forward Rate of Return ranked higher than
76.96% of 421 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 559.55, Med: 8.96, Min: -1635.32
APNHY: 13.01
Ranked among companies with meaningful Forward Rate of Return only.
Forward Rate of Return range over the past 10 years
Min: 11.5, Med: 20, Max: 22
Current: 13.01
11.5
22

More Statistics

Revenue (TTM) (Mil) $ 3,113.91
EPS (TTM) $ 0.84
Beta 1.06
Volatility % 57.5
52-Week Range $ 6.01 - 21.16
Shares Outstanding (Mil) 456

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 6
Positive ROA Y
Positive CFROA Y
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy N
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy Y
Higher Asset Turnover yoy N